Results 231 to 240 of about 51,359 (249)

Inflammatory TNBC breast cancer: Demography and clinical outcome in a large cohort of TNBC patients.

Journal of Clinical Oncology, 2014
e12036 Background: Inflammatory breast cancer is a rare but aggressive form of breast cancer. Even with modern chemotherapy along with multimodality therapy, 5-year survival is poor in the range of 30-50%. Knowledge and information about inflammatory breast cancer with TNBC phenotype are limited.
Tithi Biswas, Jimmy T Efird, Paul R. Walker, Sarah Elizabeth James, Shreya Prasad, Timothy Zagar   +5 more
openaire   +1 more source

Pembrolizumab improves EFS in TNBC

Nature Reviews Clinical Oncology, 2022
openaire   +2 more sources

Banking on metabolomics for novel therapies in TNBC

Cell Research, 2022
Aurelien Tripp, George Poulogiannis
openaire   +2 more sources

Decoding TNBC architecture

Nature Cancer
Jennifer Q. Pfeil, Sibyl Drissler, Darren C. H. Chan, Hartland W. Jackson   +3 more
openaire   +2 more sources

Metastatic TNBC

Oncology Times, 2015
openaire   +1 more source

TNBC

2017
openaire   +1 more source

TNBC

2011
openaire   +1 more source

Sacituzumab Govitecan In TNBC

Case Medical Research, 2020
openaire   +1 more source

TNBC: Immuntherapie immer bedeutsamer

gynäkologie + geburtshilfe, 2023
openaire   +1 more source

Drug-Resistant TNBC

Oncology Times, 2018
openaire   +1 more source